Literature DB >> 16204327

Electroencephalogram slowing, sleepiness and treatment response in patients with schizophrenia during olanzapine treatment.

Adam Wichniak1, Tomasz Szafranski, Aleksandra Wierzbicka, Elzbieta Waliniowska, Wojciech Jernajczyk.   

Abstract

Electroencephalogram (EEG) slowing is associated with clozapine side effects, e.g., sedation, and may predict treatment response during clozapine treatment. As olanzapine and clozapine share many pharmacological properties, we investigated whether EEG slowing during olanzapine treatment was related to therapy outcome and sleepiness in patients with schizophrenia. Participants were age- and gender-matched schizophrenic patients treated with olanzapine (n 54), receiving no pharmacological treatment (n 54), or cotreated with olanzapine and some other psychotropic drug (n 38). Their EEG recordings were assessed visually by the same rater blind to clinical data. The EEG scores were categorized using standardized forms. Patients with a poor treatment response did not differ significantly from those with a good response to treatment either in EEG patterns or in frequency of sleepiness. Olanzapine treatment was associated with increased rates of slow (70.4% vs. 22.3%) and sharp waves (22.2% vs. 7.4%), as well as of paroxysmal slow wave discharges (14.8% vs. 1.9%), but did not induce spike- or sharp-slow-wave complexes. Cotreatment with another antipsychotic further increased EEG abnormalities, whereas benzodiazepine administration diminished the olanzapine-induced EEG changes. The results show that olanzapine inducing both slow and sharp waves, as well as paroxysmal discharges, has a strong impact on EEG. However, as no spike- or sharp-slow-wave complexes were observed, the risk of epileptic seizure during olanzapine treatment can be regarded as low, as long as olanzapine is not combined with some other antipsychotic.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204327     DOI: 10.1177/0269881105056657

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

1.  Olanzapine causes a leptin-dependent increase in acetylcholine release in mouse prefrontal cortex.

Authors:  Asheley B Wathen; Emily S West; Ralph Lydic; Helen A Baghdoyan
Journal:  Sleep       Date:  2012-03-01       Impact factor: 5.849

2.  Resting EEG deficits in accused murderers with schizophrenia.

Authors:  Robert A Schug; Yaling Yang; Adrian Raine; Chenbo Han; Jianghong Liu; Liejia Li
Journal:  Psychiatry Res       Date:  2011-08-06       Impact factor: 3.222

3.  State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.

Authors:  Robert W Gould; Michael T Nedelcovych; Xuewen Gong; Erica Tsai; Michael Bubser; Thomas M Bridges; Michael R Wood; Mark E Duggan; Nicholas J Brandon; John Dunlop; Michael W Wood; Magnus Ivarsson; Meredith J Noetzel; J Scott Daniels; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropharmacology       Date:  2015-11-23       Impact factor: 5.250

4.  EEG alterations during treatment with olanzapine.

Authors:  Detlef Degner; Michael A Nitsche; Frank Bias; Eckart Rüther; Udo Reulbach
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-23       Impact factor: 5.270

5.  Generalised tonic-clonic seizures on the subtherapeutic dose of olanzapine.

Authors:  Marium Mansoor; Mohammad Hanif Mesiya; Aisha Sanober Chachar
Journal:  BMJ Case Rep       Date:  2019-12-29

6.  Olanzapine-induced electroencephalographic changes reversed by lamotrigine.

Authors:  Prasuna L Velur; Giridhar P Kalamangalam
Journal:  Ann Indian Acad Neurol       Date:  2012-10       Impact factor: 1.383

7.  Targeting Neural Synchrony Deficits is Sufficient to Improve Cognition in a Schizophrenia-Related Neurodevelopmental Model.

Authors:  Heekyung Lee; Dino Dvorak; André A Fenton
Journal:  Front Psychiatry       Date:  2014-02-14       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.